Healthcare

Invion Limited (ASX:IVX)

Industry Group : Pharmaceuticals, Biotechnology & Life Sciences | Industry Group Name : Pharmaceuticals

Market Price : AUD 0.0210 (0%)

(as on 2022-01-19 18:41:29 AEDT)

Market Cap : AUD 134.747 M

Previous Close Open Close* Day Range 52 WEEK HIGH LOW
0.021 0.021 0.021 0.020L 0.022 H 0.008L 0.034 H
Last Trade 0.021
Change% 0.0000
52 W H/L 0.034/0.008
EBITDA -1.294 M
NPAT After Abnormal Items -1.483 M
Equity 4.791 M
ROE% -30.96%
Total Liabilities 851,496
Total Revenue 2.419 M
Cash and Cash Equivalents 1.037 M

Stock Information

Share price 0.021
Market Cap 134.747 M
Price/Gross Cash Flow -94.72
Dividend Yield Excluding Special 0.00%
Ending Shares 5.54 B
52-Week Range 0.034-0.008
P/E ratio 0.000
Sector P/E --
EPS -0.03
EV/EBITDA --
Net Profit Margin (%) -63.65%
Gross Cash Flows Per Share -0.00
Net Gearing -21.64%
Gross DPS (AUD) 0
Gross Dividend Yield (Annualized) 0.00%
Earnings Yield 0.000
Net Tangible Asset (NTA) 0.00
Sales Per Share 0.00
Book Value Per Share 0.00

Announcements

Heading Date/Time
Proposed issue of securities - IVX  16/11/2021 11:05AM
Proposed issue of securities - IVX  16/11/2021 11:03AM
Proposed issue of securities - IVX  16/11/2021 11:01AM
Capital Raising and expansion of Photosoft Territory  16/11/2021 11:00AM
Trading Halt  12/11/2021 8:51AM
Results of Annual General Meeting  09/11/2021 4:33PM
AGM Presentation  09/11/2021 12:49PM
Jobkeeper Payments Notice  01/11/2021 9:14AM
Appointment of Company Secretary  29/10/2021 1:20PM
Further Information on Proof of Concept Pilot Study  29/10/2021 8:52AM
Complete Regression of TNBC Tumours and Protective Immunity  28/10/2021 9:43AM
Activities Report and Appendix 4C  21/10/2021 2:53PM
Grant of ASX Waiver  08/10/2021 9:24AM
Notice of Annual General Meeting/Proxy Form  08/10/2021 8:56AM
Change in substantial holding  07/10/2021 9:25AM
Change of Director's Interest Notice- Robert Merriel  06/10/2021 10:40AM
Section 708A Cleansing Statement  06/10/2021 10:39AM
Change of Director's Interest Notice - Alistair Bennallack  06/10/2021 10:37AM
Application for quotation of securities - IVX  06/10/2021 10:35AM
Section 708A Cleansing Statement  04/10/2021 10:11AM
Change of Director's Interest Notice- Robert Merriel  04/10/2021 10:10AM
Application for quotation of securities - IVX  04/10/2021 10:08AM
Application for quotation of securities - IVX  04/10/2021 10:02AM
Change of Director's Interest Notice - Alistair Bennallack  04/10/2021 9:53AM
Notification regarding unquoted securities - IVX  04/10/2021 9:47AM
Change of Director's Interest Notice- Thian Chew  04/10/2021 9:38AM
Notification regarding unquoted securities - IVX  04/10/2021 9:35AM
Results of General Meeting  23/09/2021 2:18PM
Change of Director's Interest Notice- Alan Yamashita  17/09/2021 3:04PM

Similar Companies

Related Articles

Load More

About Company

Australian life sciences firm Invion Limited (ASX:IVX) is focused on transforming Photodynamic Therapy (PDT) to develop pioneering and effective cancer therapies.

PDT is an established treatment that enhances the utilisation of non-toxic photosensitisers as well as visible light for destroying cancer cells and invigorating the immune system. Invion is engaged in developing more effective, next-generation PDT that overcomes the multiple shortcomings of the existing PDT therapies.

Invion is a global leader in the R&D of Photosoft™ technology. The Company has the license as well as distribution rights to the Photosoft™ technology in Australia and New Zealand.

IVX has developed a new intravenous (IV) and topically administered product appropriate for solid tumours (prostate, ovarian, and lung cancer) and skin cancer.

Invion has signed an agreement with RMW Cho Group Limited for the clinical development of PhotosoftTM technology across the globe. RMW Cho also offers non-dilutive funding to Invion for the research and clinical trials of the PhotosoftTM Technology through an R&D services agreement.

The Company has partnered with world-leading medical research institutes for developing a novel photosensitiser named IVX-PDT. Invion is confident that this novel photosensitiser will improve the treatment of challenging solid cancers and skin cancers. The objective of developing IVX-PDT is to be more efficient in targeting and destroying cancer cells with no harmful side effects and negligible discomfort.

With a substantial clinical and commercial potential of its assets, Invion is advancing multiple programs and initiate pre-clinical and clinical studies in partnership with Hudson Institute of Medical Research and The Peter MacCallum Cancer Centre.

IVX and its research partners are targeting cancers, including topical indications for Actinic Keratosis and Basal Cell Carcinoma as well as intravenous indications for mesothelioma, rare cancer associated with asbestos exposure.

Corporate Information

company address Level 4, 100 Albert Road, SOUTH MELBOURNE, VIC, AUSTRALIA, 3205

company phone+61 3 9692 7222

company email[email protected]

company websitehttp://www.inviongroup.com

Dividends

Year-end Date Franking DPS (AUD) Dividend Yield
30/06/2021 -- 0.000 0.00%
30/06/2020 -- 0.000 0.00%
30/06/2019 -- 0.000 0.00%
30/06/2018 -- 0.000 0.00%
30/06/2017 -- 0.000 0.00%
30/06/2016 -- 0.000 0.00%
30/06/2015 -- 0.000 0.00%
30/06/2014 -- 0.000 0.00%
30/06/2013 -- 0.000 0.00%
30/06/2012 -- 0.000 0.00%

Event Calendar

Event Type Event Date Event Year
Report (Annual) 2022-08-04 2022
Report (Prelim) 2022-08-04 2022
Report (Interim) 2022-02-24 2022

Financials

Breakdown 30/06/2021 30/06/2020 30/06/2019 30/06/2018 30/06/2017
Trading Revenue -- -- -- -- --
Other Revenue 2.419 M 3.549 M 3.852 M 888,527 173,987
Total Revenue 2.419 M 3.549 M 3.852 M 888,527 173,987
Interest Income 86 546 1,334 1,072 420
Interest Expenses 0 0 0 -117,927 -144,380
Expenses -3.624 M -4.225 M -6.09 M -1.664 M -840,417
EBITDA -1.205 M -676,534 -2.238 M -775,649 -666,430
Depreciation and Amortization -277,867 -277,906 -309,568 -1.325 M -1.245 M
Depreciation -2,867 -2,906 -1,235 -2,673 -2,983
Amortisation -275,000 -275,000 -308,333 -1.322 M -1.242 M
EBIT -1.483 M -954,440 -2.548 M -2.101 M -1.911 M
Pre Tax Profit -1.483 M -953,894 -2.546 M -2.218 M -2.055 M
Tax Expense 0 0 0 -652,494 4.256 M
Net Profit After Tax -1.483 M -953,894 -2.546 M -2.87 M 2.2 M
Minority Interest 0 0 0 0 0
Preference Dividend 0 0 0 0 0
Net Abnormal Items 0 0 0 -2 M -4.4 M
Reported Net Profit After Abnormal Items -1.483 M -953,894 -1.064 M -4.87 M -2.2 M
Ending Shares 5.54 B 5.501 B 5.501 B 6.178 B 2.074 B
Weighted Average Shares 5.526 B 5.501 B 5.495 B 4.29 B 1.788 B
EPS After Abnormal Items (cents) -0.03 -0.02 -0.02 -0.11 -0.12
Breakdown 30/06/2021 30/06/2020 30/06/2019 30/06/2018 30/06/2017
Total Current Assets 1.076 M 916,861 942,158 3.061 M 1.007 M
Total Non Current Assets 4.566 M 4.844 M 5.12 M 7.288 M 4.805 M
Total Assets 5.642 M 5.761 M 6.062 M 10.349 M 5.812 M
Total Current Liabilities 851,496 326,822 604,712 1.782 M 1.805 M
Total Non Current Liabilities 0 0 0 661,032 0
Total Liabilities 851,496 326,822 604,712 2.443 M 1.805 M
Net Assets 4.791 M 5.434 M 5.457 M 7.906 M 4.007 M
Breakdown 30/06/2021 30/06/2020 30/06/2019 30/06/2018 30/06/2017
Net Operating Cash 417,975 -152,470 -2.106 M 707,087 -247,139
Net Invested Cash 0 0 -13,608 0 53,865
Net Financing Cash Flows 0 0 0 1.268 M 678,866
Beginning Cash 618,843 771,313 2.891 M 917,486 437,399
End Cash Position 1.037 M 618,843 771,313 2.891 M 917,486
Exchange Rate Adjustments 0 0 -757 -1,357 -5,505
Other Cash Adjustments 0 0 0 0 0
Ending Cash 1.037 M 618,843 771,313 2.891 M 917,486

© Morningstar, Inc. 2021. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the market indices, commodities and regulatory news headlines, and other data or content contained herein to be accurate, complete, or timely, and nor shall they have any liability for its use or distribution. The data contained herein: (1) is proprietary to Morningstar and/or its affiliates (collectively, “Morningstar”) and/or their content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Our publications, ratings and products should be viewed as an additional investment resource, and not as your sole source of information. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your financial situation, contact a professional financial adviser. Some material is copyrighted and published under licence from ASX Operations Pty. Ltd. ACN 004523782.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK